Clinical Trial: Lipid Efficacy/Tolerability Study (0524A-020)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholest

Brief Summary: A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Reductions of LDL-C concentrations at 24 weeks and better tolerability [ Time Frame: at 24 weeks ]

Original Primary Outcome: Reductions of LDL-C concentrations at 24 weeks and better tolerability

Current Secondary Outcome: Elevations in HDL-C concentrations at 24 weeks [ Time Frame: at 24 weeks ]

Original Secondary Outcome: Elevations in HDL-C concentrations at 24 weeks

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: December 21, 2005
Date Started: December 2005
Date Completion:
Last Updated: July 24, 2015
Last Verified: July 2015